Fgf variants and methods for use thereof
CA 2483602 C · Owner: Bogin, Oren · Inventors: Bogin, Oren; Yayon, Avner
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia osteoporosis and , enhancing bone fracture healing and cartilage healing processes are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 9, 2003 and granted October 15, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.